{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:08:08Z","timestamp":1761512888493},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1038\/sj.bjc.6605875","type":"journal-article","created":{"date-parts":[[2010,10,12]],"date-time":"2010-10-12T20:00:20Z","timestamp":1286913620000},"page":"1325-1330","source":"Crossref","is-referenced-by-count":14,"title":["Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer"],"prefix":"10.1038","volume":"103","author":[{"given":"F","family":"Oshita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,12]]},"reference":[{"key":"BF6605875_CR1","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1200\/JCO.2002.03.055","volume":"20","author":"KS Albain","year":"2002","unstructured":"Albain KS, Crowley JJ, Turrisi III AT, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB (2002) Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20: 3454\u20133460","journal-title":"J Clin Oncol"},{"key":"BF6605875_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JTO.0b013e3181ce3e00","volume":"5","author":"BR Bastos","year":"2010","unstructured":"Bastos BR, Hatoum GF, Walker GR, Tolba K, Takita C, Gomez J, Santos ES, Lopes G, Raez LE (2010) Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer. J Thorac Oncol 5: 533\u2013539","journal-title":"J Thorac Oncol"},{"key":"BF6605875_CR3","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.1200\/JCO.2005.03.070","volume":"23","author":"P Fournel","year":"2005","unstructured":"Fournel P, Robinet G, Thomas P, Souquet PJ, L\u00e9na H, Vergnen\u00e9gre A, Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daur\u00e9s JP, Mornex F, P\u00e9rol M, Groupe Lyon-Saint-Etienne d\u2019Oncologie Thoracique-Groupe Fran\u00e7ais de Pneumo-Canc\u00e9rologie (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d\u2019Oncologie Thoracique-Groupe Fran\u00e7ais de Pneumo-Canc\u00e9rologie NPC 95-01 Study. J Clin Oncol 23: 5910\u20135917","journal-title":"J Clin Oncol"},{"key":"BF6605875_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.22817","volume":"110","author":"M Fukuda","year":"2007","unstructured":"Fukuda M, Soda H, Fukuda M, Kinoshita A, Nakamura Y, Nagashima S, Takatani H, Tsukamoto K, Kohno S, Oka M (2007) Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study. Cancer 110: 606\u2013613","journal-title":"Cancer"},{"key":"BF6605875_CR5","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","volume":"21","author":"M Fukuoka","year":"2003","unstructured":"Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21: 2237\u20132246","journal-title":"J Clin Oncol"},{"key":"BF6605875_CR6","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/JCO.1999.17.9.2692","volume":"17","author":"K Furuse","year":"1999","unstructured":"Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692\u20132699","journal-title":"J Clin Oncol"},{"key":"BF6605875_CR7","doi-asserted-by":"publisher","first-page":"5057s","DOI":"10.1158\/1078-0432.CCR-05-9012","volume":"11","author":"D Gandara","year":"2005","unstructured":"Gandara D, Narayan S, Lara Jr PN, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S (2005) Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res 11: 5057s\u20135062s","journal-title":"Clin Cancer Res"},{"key":"BF6605875_CR8","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1200\/JCO.2003.04.197","volume":"21","author":"DR Gandara","year":"2003","unstructured":"Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara Jr PN, Burris H, Gumerlock P, Kuebler JP, Bearden III JD, Crowley J, Livingston R, Southwest Oncology Group (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: II phase Southwest Oncology Group Study S9504. J Clin Oncol 21: 2004\u20132010","journal-title":"J Clin Oncol"},{"key":"BF6605875_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0378-4274(90)90161-E","volume":"52","author":"Y Kameyama","year":"1990","unstructured":"Kameyama Y, Okazaki N, Nakagawa M, Koshida H, Nakamura M, Gemba M (1990) Nephrotoxicity of a new platinum compaound, 254S, evaluated with rat kidney cortical slices. Toxicol Lett 52: 15\u201324","journal-title":"Toxicol Lett"},{"key":"BF6605875_CR10","first-page":"202","volume":"7","author":"F Kanzawa","year":"2001","unstructured":"Kanzawa F, Koizumi F, Koh Y, Nakamura T, Tatsumi Y, Fukumoto H, Saijo N, Yoshioka T, Nishio K (2001) In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res 7: 202\u2013209","journal-title":"Clin Cancer Res"},{"key":"BF6605875_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/JTO.0b013e318031cd3c","volume":"2","author":"CJ Langer","year":"2007","unstructured":"Langer CJ, Somer R, Litwin S, Feigenberg S, Movsas B, Maiale C, Sherman E, Millenson M, Nicoloau N, Huang C, Treat J (2007) Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma. J Thorac Oncol 2: 203\u2013209","journal-title":"J Thorac Oncol"},{"key":"BF6605875_CR12","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1200\/JCO.2005.00.992","volume":"23","author":"T Mitsudomi","year":"2005","unstructured":"Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513\u20132520","journal-title":"J Clin Oncol"},{"key":"BF6605875_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, West Japan Oncology Group (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121\u2013128","journal-title":"Lancet Oncol"},{"key":"BF6605875_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947\u2013957","journal-title":"N Engl J Med"},{"key":"BF6605875_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/sj.bjc.6605152","volume":"101","author":"F Ohyanagi","year":"2009","unstructured":"Ohyanagi F, Yamamoto N, Horiike A, Harada H, Kozuka T, Murakami H, Gomi K, Takahashi T, Morota M, Nishimura T, Endo M, Nakamura Y, Tsuya A, Horai H, Nishio M (2009) Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Br J Cancer 101: 225\u2013231","journal-title":"Br J Cancer"},{"key":"BF6605875_CR16","first-page":"251","volume":"6","author":"F Oshita","year":"2007","unstructured":"Oshita F, Saito H, Yamada K (2007) Feasible combination chemotherapy with nedaplatin and irinotecan for patients with non-small cell lung cancer and multiple high-risk factors. J Exp Ther Oncol 6: 251\u2013256","journal-title":"J Exp Ther Oncol"},{"key":"BF6605875_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00280-003-0615-y","volume":"52","author":"F Oshita","year":"2003","unstructured":"Oshita F, Yamada K, Kato Y, Ikehara M, Noda K, Tanaka G, Nomura I, Suzuki R, Saito H (2003) Phase I\/II study of an escalating dose of nedaplatin in combination with irinotecan for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 52: 73\u201378","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6605875_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00280-007-0626-1","volume":"62","author":"F Oshita","year":"2008","unstructured":"Oshita F, Yamada K, Saito H, Noda K (2008) Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer. Cancer Chemother Pharmacol 62: 465\u2013470","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6605875_CR19","first-page":"343","volume":"4","author":"F Oshita","year":"2004","unstructured":"Oshita F, Yamada K, Saito H, Noda K, Hamanaka N, Ikehara M, Tanaka G (2004) Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer. J Exp Ther Oncol 4: 343\u2013348","journal-title":"J Exp Ther Oncol"},{"key":"BF6605875_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1200\/JCO.2004.09.053","volume":"22","author":"DG Pfister","year":"2004","unstructured":"Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker Jr S, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR (2004) American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22: 330\u2013353","journal-title":"J Clin Oncol"},{"key":"BF6605875_CR21","doi-asserted-by":"publisher","first-page":"7078","DOI":"10.1200\/jco.2004.22.14_suppl.7078","volume":"22","author":"N Ready","year":"2004","unstructured":"Ready N, Herndon J, Vokes E, Bogard J, Crawford J, Dipetrillo T, Green M (2004) Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small cell lung cancer (NSCLC): a CALGB stratified phase II trial. Proc Am Soc Clin Oncol 22: 7078","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6605875_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1097\/01243894-200610000-00009","volume":"1","author":"I Sekine","year":"2006","unstructured":"Sekine I, Nokihara H, Sumi M, Saijo N, Nishiwaki Y, Ishikura S, Mori K, Tsukiyama I, Tamura T (2006) Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol 1: 810\u2013815","journal-title":"J Thorac Oncol"},{"key":"BF6605875_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trial. Control Clin Trial 10: 1\u201310","journal-title":"Control Clin Trial"},{"key":"BF6605875_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"9 Suppl 9","key":"BF6605875_CR25","first-page":"13","volume":"16","author":"HG Wu","year":"2002","unstructured":"Wu HG, Choy H (2002) Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer. Oncology (Williston Park) 16 (9 Suppl 9): 13\u201318","journal-title":"Oncology (Williston Park)"},{"key":"BF6605875_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2004.03.004","volume":"46","author":"P Zatloukal","year":"2004","unstructured":"Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P, Pecen L (2004) Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46: 87\u201398","journal-title":"Lung Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605875.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605875","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605875.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:47:04Z","timestamp":1684414024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["BF6605875"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605875","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}